Nadolol
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Nadolol: From Beta-Blocker Therapy to Malignant Hypertensive Renal Disease
One-Sentence Summary
Nadolol is an oral non-selective beta-blocker marketed in the United States as generic tablets. The provided records do not list its approved indications. The TxGNN model predicts it may be effective for malignant hypertensive renal disease, but there are 0 clinical trials and no drug-specific publications supporting this prediction. It is a model-only signal (Evidence Level L5).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the provided US license records |
| Predicted New Indication | Malignant hypertensive renal disease |
| TxGNN Prediction Score | 99.59% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (all listed licenses are ANDAs, i.e. generics) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the record. Based on known pharmacology, nadolol is a non-selective beta-blocker that lowers blood pressure and suppresses renin release. That is biologically plausible in renin-driven hypertensive kidney injury, and it is the only mechanistic support for the prediction.
There are also reasons for caution:
- Malignant hypertension is a hypertensive emergency, usually managed with IV agents. An oral long-acting beta-blocker is not a natural fit.
- The original indication field is empty, so the relationship between the old and new indications could not be cross-checked.
- The identical scores for related predictions (malignant renovascular hypertension, and the two pulmonary hypertension entries) suggest a shared graph neighborhood rather than independent evidence.
Other predicted indications (all L5, all Hold):
| Rank | Predicted Indication | Score | Comment |
|---|---|---|---|
| 2 | Malignant renovascular hypertension | 99.59% | Renin link is theoretical. RAAS inhibitors are the usual choice, and there is no evidence for nadolol. |
| 3 | Pulmonary hypertension owing to lung disease and/or hypoxia | 99.53% | The 20 retrieved papers are general hypoxia biology, not nadolol studies. |
| 4 | Pulmonary hypertension with unclear multifactorial mechanism | 99.53% | Beta-blockers are generally not recommended in PH because they can reduce cardiac output and right ventricular function. |
| 5 | Braddock syndrome | 99.43% | Ultra-rare disorder. The score likely comes from graph proximity via the PH phenotype. |
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
No literature directly studying nadolol or beta-blockers in malignant hypertensive renal disease was found. Literature was retrieved only for the rank 3 indication (pulmonary hypertension owing to lung disease and/or hypoxia). Those 20 papers appear to be keyword matches on “hypoxia”, and none studies nadolol. There are no RCTs; the examples below are the reviews and basic-research papers among them.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33862277 | 2021 | Review | Ageing Res Rev | Hypoxia and brain aging. Not drug-specific. |
| 34618295 | 2022 | Review | Metab Brain Dis | Clinical evidence and molecular mechanisms of hypoxia-induced cognitive impairment. Not drug-specific. |
| 34535359 | 2021 | Review | Clin Oncol | Therapeutic modification of tumour hypoxia. Not related to nadolol. |
| 11172576 | 2000 | Review | Respir Care Clin N Am | Basic mechanisms of hypoxemia. Background physiology only. |
| 37328448 | 2023 | Preclinical | Adv Sci (Weinheim) | NAT10/HIF-1α glycolysis loop in gastric cancer. Unrelated. |
US Market Information
The records list 20 licenses in total; 5 are shown. All are oral tablets, and none includes approved-indication text.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA212856 | NADOLOL (VGYAAN Pharmaceuticals LLC) | Tablet | Not listed in the record |
| ANDA210955 | Nadolol (Unichem Pharmaceuticals (USA), Inc.) | Tablet | Not listed in the record |
| ANDA203455 | Nadolol (BluePoint Laboratories) | Tablet | Not listed in the record |
| ANDA207761 | Nadolol (Zydus Lifesciences Limited) | Tablet | Not listed in the record |
| ANDA203455 | Nadolol (Cipla USA Inc.) | Tablet | Not listed in the record |
Safety Considerations
Please refer to the package insert for safety information. Package-insert warnings and contraindications were not captured in the data, and no drug-drug interaction records were found.
Class-level concerns raised in the prediction review:
- Bronchospasm: non-selective beta-blockers such as nadolol can provoke bronchospasm and are generally avoided in significant chronic lung disease, which is the typical context for the hypoxia-related PH group.
- Pulmonary hypertension: beta-blockers can reduce cardiac output and right ventricular function.
Conclusion and Next Steps
Decision: Hold
Rationale: All five predictions are model-only (L5) with no clinical trials and no drug-specific literature. The clinical fit for the top prediction is weak, and the safety profile is a concern for the pulmonary hypertension predictions. The package-insert safety review is also incomplete, which blocks progression to safety screening.
To proceed, the following is needed:
- FDA package insert warnings and contraindications (download and parse the label)
- Mechanism of action data from DrugBank (DB01203)
- Original approved indications, to assess the link to the predicted indication
- A targeted literature search for nadolol or beta-blockers in malignant hypertension and renin-mediated hypertensive nephropathy
- Clinical justification for an oral long-acting beta-blocker in a hypertensive emergency setting
- Route compatibility assessment (currently pending)
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.